Viewing StudyNCT00051116



Ignite Creation Date: 2024-05-05 @ 11:29 AM
Last Modification Date: 2024-10-26 @ 9:08 AM
Study NCT ID: NCT00051116
Status: COMPLETED
Last Update Posted: 2009-09-23
First Post: 2003-01-03

Brief Title: A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Sponsor: Celgene Corporation
Organization: Celgene

Conditions & Keywords Data

Conditions:
Name
Multiple Myeloma
Keywords:
Name View
CC-5013 View
Multiple Myeloma View
Revimid View
CC5013 View